NCT03285620View on ClinicalTrials.gov

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Hepatitis B
Interventions
DRUG

AL-034

Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2

DRUG

Placebo

Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.

Trial Locations (1)

Unknown

Auckland Clinical Studies, Ltd., Auckland

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY